Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessBluePrint breast cancer molecular subty** recognizes single and dual subtype tumors with implications for therapeutic guidance
BluePrint (BP) is an 80-gene molecular subty** test that classifies early-stage breast cancer (EBC) into Basal, Luminal, and HER2 subtypes. In most cases, breast tumors have one dominant subtype, representat...